The economics of esketamine 

Esketamine offers an important new tool to treat depression — but is it cost-effective? The proposed price would have to be shaved 25 percent to be economical, according to a new ICER report. The Johnson & Johnson nasal spray, which will be sold under the trade name Spravato, will have a list price of $590 to $885 per treatment — with a potential yearly tab of nearly $50,000. 

(One journalist figures the cost of a comparable drug would cost a fraction of this amount if acquired streetside, but her editor would be unlikely to pass detailed information along to readers.) 

Read more.